BTIG starts coverage with a Buy rating and $72 price target for Bright Minds Biosciences. BMB‑201 showed up to 100% improvement in headache symptoms vs. sumatriptan in preclinical tests. Get the data-driven signals to profit from September volatility ( for free ) →

BMB-101 showed efficacy in Dravet Syndrome and generalized seizure models during preclinical studies. Chardan projects over $1 billion peak sales in DEE and absence epilepsy and assigns an $80 price target. Get prepared for the Fed's next move-live with Matt Maley on Wednesday, May 7 at 6 PM ET. ...

NEW YORK and VANCOUVER, British Columbia, Feb. 24, 2025 ( GLOBE NEWSWIRE ) -- Bright Minds Biosciences, Inc. ( "Bright Minds," "BMB" or the "Company" ) ( NASDAQ: DRUG ) , a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, ...

NEW YORK and VANCOUVER, British Columbia, Feb. 24, 2025 ( GLOBE NEWSWIRE ) -- Bright Minds Biosciences, Inc. ( "Bright Minds," "BMB" or the "Company" ) DRUG, a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and ...

Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. BMO Capital analyst Jack Matten initiated coverage on Prudential Financial, Inc.